Histogen Inc
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its prec… Read more
Histogen Inc (HSTO) - Total Assets
Latest total assets as of September 2023: $5.82 Million USD
Based on the latest financial reports, Histogen Inc (HSTO) holds total assets worth $5.82 Million USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Histogen Inc - Total Assets Trend (2013–2022)
This chart illustrates how Histogen Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Histogen Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Histogen Inc's total assets of $5.82 Million consist of 70.6% current assets and 29.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 63.5% |
| Accounts Receivable | $99.00K | 0.5% |
| Inventory | $400.00K | 2.1% |
| Property, Plant & Equipment | $5.09 Million | 26.7% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2022)
This chart illustrates how Histogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Histogen Inc's current assets represent 70.6% of total assets in 2022, a decrease from 99.9% in 2013.
- Cash Position: Cash and equivalents constituted 63.5% of total assets in 2022, up from 7.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is property, plant & equipment at 26.7% of total assets.
Histogen Inc Competitors by Total Assets
Key competitors of Histogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Histogen Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Histogen Inc generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Histogen Inc is currently not profitable relative to its asset base.
Histogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.05 | 11.69 | 2.56 |
| Quick Ratio | 4.05 | 11.26 | 2.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.11 Million | $ 14.94 Million | $ 28.91 Million |
Histogen Inc - Advanced Valuation Insights
This section examines the relationship between Histogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.02 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -30.0% |
| Total Assets | $19.07 Million |
| Market Capitalization | $85.44K USD |
Valuation Analysis
Below Book Valuation: The market values Histogen Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Histogen Inc's assets decreased by 30.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Histogen Inc (2013–2022)
The table below shows the annual total assets of Histogen Inc from 2013 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $19.07 Million | -29.99% |
| 2021-12-31 | $27.25 Million | +81.48% |
| 2020-12-31 | $15.01 Million | +410.30% |
| 2019-12-31 | $2.94 Million | -93.97% |
| 2018-12-31 | $48.80 Million | -40.44% |
| 2017-12-31 | $81.94 Million | -0.47% |
| 2016-12-31 | $82.32 Million | +107.22% |
| 2015-12-31 | $39.73 Million | +3.33% |
| 2014-12-31 | $38.45 Million | -32.47% |
| 2013-12-31 | $56.94 Million | -- |